𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Platinum analogue combination chemotherapy: Cisplatin, carboplatin, and methotrexate in patients with metastatic urothelial tract tumors. A phase II trial with evaluation of prognostic factors

✍ Scribed by Lisa Sengeløv; Ole Steen Nielsen; Claus Kamby; Hans Von Der Maase

Publisher
John Wiley and Sons
Year
1995
Tongue
English
Weight
600 KB
Volume
76
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pretreatment prognostic factors for surv
Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine
✍ Joaquim Bellmunt; Joan Albanell; Luis Paz-Ares; Miguel A. Climent; Jose L. Gonzá 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB

## Background: New chemotherapeutic agents, including paclitaxel and gemcitabine, are active in advanced bladder carcinoma, and combination regimens with these agents have shown promising results. unlike conventional chemotherapy regimens, such as methotrexate, vinblastine, doxorubicin, and cisplat

Platinum-free combination chemotherapy i
Platinum-free combination chemotherapy in patients with advanced or metastatic transitional cell carcinoma : A Phase I/II trial of gemcitabine, paclitaxel, and methotrexate
✍ Primo N. Lara Jr; Frederick J. Meyers; Lisa Y. Law; Nancy A. Dawson; Joan Housto 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB 👁 2 views

## Abstract ## BACKGROUND Platinum‐based regimens have improved response rates and survival in patients with advanced transitional cell carcinoma (TCC) of the urothelial tract. However, the toxicities of platinum‐based chemotherapy are considerable. Regimens with reduced toxicity that are applicab

Phase II trial of intermediate dose meth
Phase II trial of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma
✍ Paul M. Dodd; John A. McCaffrey; Madhu Mazumdar; Howard Scher; Vaia Vlamis; Gera 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB 👁 3 views

## Background: This study was undertaken to determine whether the use of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin as first-line therapy increases the proportion of major responders and overall survival in patients with unresectable or metastatic tra